Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.58 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2288086 | 0.90 | SLC6A4 (0.59) | SLC6A4HTR6S1PR1S1PR5PTGER1 | |
| SCHEMBL2287592 | 0.86 | SLC6A4 (0.55) | SLC6A4HTR6 | |
| Trifluoroacetic Acid SCHEMBL2285162 | 0.80 | SLC6A4 (0.80) | SLC6A4HTR6 | |
| SCHEMBL2283183 | 0.79 | SLC6A4 (0.57) | SLC6A4HTR6PTGER1 | |
| SCHEMBL2287842 | 0.79 | SLC6A4 (0.40) | SLC6A4HTR6 | |
| SCHEMBL2282636 | 0.78 | SLC6A4 (0.58) | SLC6A4HTR6 | |
| SCHEMBL2282282 | 0.78 | HTR2C (0.44) | SLC6A4 | |
| SCHEMBL2281964 | 0.78 | HTR2C (0.47) | SLC6A4HTR6MAPT | |
| SCHEMBL2280104 | 0.74 | SLC6A4 (0.50) | SLC6A4HTR6 | |
| SCHEMBL2285609 | 0.74 | SLC6A4 (1.00) | SLC6A4HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8642583-B2 | Serotonin receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2014-02-04 | — | — | US | disclosed |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038943-A1 | SEROTONIN RECEPTOR MODULATOR | HTR2C, HTR2A, HTR1A | SLC6A4 19/4885HTR6 6/4885MAPT 2490/4885 |
| US-20110207714-A1 | SEROTONIN RECEPTOR MODULATORS | HTR1A, HTR2A, HTR2C | SLC6A4 19/4885HTR6 4/4885MAPT 2509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.